Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”

Thumbnail
Identificadores

URI: http://hdl.handle.net/10498/32774

DOI: https://doi.org/10.1007/s13555-024-01106-2

ISSN: 2190-9172

ISSN: 2193-8210

Files
Statistics
Metrics and citations
 
Share
Export
EndNoteBibTexRIS
Metadata
Show full item record
Author/s
Rand, K.; Ramos-Goñi, J. M.; Akmaz, B.; Solé-Feu, L.; Armario Hita, José CarlosAuthority UCA
Date
2024-03-05
Department
Medicina
Source
Dermatology and Therapy
Abstract
Letter
Collections
Attribution-NonCommercial 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial 4.0 Internacional